The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Over the last 7 days, the United States market ... Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry New with Dexcom G7 15 Day Longe DexCom stock was on the rise ...

In a head-to-head study, three continuous glucose monitoring systems show different measurements in the same person, which ...

Personal continuous glucose monitors are accurate at measuring glucose levels in most ranges for hospitalized patients with ...

The proportion of adolescents living with overweight and obesity in England increased by 50% over 15 years, and many related ...

Some of the key drivers for market growth are the rising prevalence of chronic conditions Market, rising geriatric population, and technology advance ...

There are several CGMs that have been cleared by the FDA and are available over-the-counter, including Dexcom’s Stelo and Abbott’s ... Aroda VR, et al. 7. Diabetes technology: Standards of Care in ...

(NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, ...

San Diego-based Dexcom, a leading diabetes technology company known for its wearable glucose monitors, is expanding its NIL ...

Dexcom is focused on its applications in the type 2 diabetes market, noting, for example, that it provides an option for people who don’t have insurance coverage for CGM – which, according to ...

In 2017, Lilly started working with Dexcom on the partnership, which aims to combine devices, drugs and technology to improve the care of people with diabetes and also to help big pharma stay ...